Research Article
The Diagnostic Value of the Systemic Immune-Inflammation Index for Venous Thromboembolism in Lung Cancer Patients: A Retrospective Study
Table 1
Comparison of clinical data between VTE groups and non-VTE groups.
| | Variable | VTE ( = 86) | Non-VTE group ( = 283) | | -value |
| | Gender | | | 1.631 | 0.202 | | Female | 37 (57.0%) | 144 (50.9%) | | | | Male | 49 (43.0%) | 139 (49.1%) | | | | Age | | | 11.929 | <0.001 | | >65 | 39 (45.3%) | 73 (25.8%) | | | | ≤65 | 47 (54.7%) | 210 (74.2%) | | | | BMI | | | 0.407 | 0.524 | | >28 | 6 (7.0%) | 26 (9.2%) | | | | ≤28 | 80 (93.0%) | 257 (90.8%) | | | | Smoking | | | 0.206 | 0.650 | | Yes | 35 (40.7%) | 123 (43.5%) | | | | No | 51 (59.3%) | 160 (56.5%) | | | | Vessel disease | | | 0.006 | 0.936 | | Yes | 1 (1.2%) | 3 (1.1%) | | | | No | 85 (98.8%) | 280 (98.9%) | | | | Pathological type | | | 6.608 | 0.037 | | Adenocarcinoma | 53 (61.6%) | 133 (47.0%) | | | | SCC | 21 (24.4%) | 80 (28.3%) | | | | SCLC | 12 (14.0%) | 70 (24.7%) | | | | Metastasis | | | 19.47 | <0.001 | | Yes | 47 (55.3%) | 82 (29.2%) | | | | No | 38 (44.7%) | 199 (70.8%) | | | | Molecular subtypes | | | 9.574 | 0.002 | | Wild | 57 (66.3%) | 232 (82.0%) | | | | Mutation | 29 (33.7%) | 51 (18.0%) | | | | Antitumor therapy | | | 5.611 | 0.018 | | Yes | 70 (81.4%) | 193 (68.2%) | | | | No | 16 (18.6%) | 90 (31.8%) | | |
|
|
Notes: Abbreviations: ALK: the anaplastic lymphoma kinase; EGFR: the epidermal growth factor receptor; KRAS: the Kirsten rat sarcoma viral oncogene homolog; ROS1: the c-ROS oncogene 1; SCC: squamous cell carcinoma; SCLC: small cell lung cancer.
|
